

John J Turchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/179423/publications.pdf>

Version: 2024-02-01

90
papers

3,885
citations

117625

34
h-index

144013

57
g-index

94
all docs

94
docs citations

94
times ranked

4792
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA repair targeted therapy: The past or future of cancer treatment?. , 2016, 160, 65-83.		307
2	Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Research, 2008, 18, 64-72.	12.0	242
3	Chemotherapy induced DNA damage response. Cancer Biology and Therapy, 2013, 14, 379-389.	3.4	216
4	Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Molecular Cell, 2021, 81, 3128-3144.e7.	9.7	142
5	Association and regulation of the BLM helicase by the telomere proteins TRF1 and TRF2. Human Molecular Genetics, 2004, 13, 1919-1932.	2.9	139
6	Novel function of the flap endonuclease 1 complex in processing stalled DNA replication forks. EMBO Reports, 2005, 6, 83-89.	4.5	132
7	Cisplatin Sensitizes Cancer Cells to Ionizing Radiation via Inhibition of Nonhomologous End Joining. Molecular Cancer Research, 2005, 3, 277-285.	3.4	130
8	Effect of DNA Polymerases and High Mobility Group Protein 1 on the Carrier Ligand Specificity for Translesion Synthesis past Platinum~DNA Adducts~. Biochemistry, 1999, 38, 11026-11039.	2.5	129
9	RPA Phosphorylation in Mitosis Alters DNA Binding and Protein~Protein Interactions~. Biochemistry, 2003, 42, 3255-3264.	2.5	118
10	Modulating DNA Repair Pathways to Improve Precision Genome Engineering. ACS Chemical Biology, 2018, 13, 389-396.	3.4	99
11	DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target. Clinical Cancer Research, 2011, 17, 6973-6984.	7.0	97
12	Replication Protein A (RPA) Binding to Duplex Cisplatin-damaged DNA Is Mediated through the Generation of Single-stranded DNA. Journal of Biological Chemistry, 1999, 274, 14972-14978.	3.4	92
13	The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer. Clinical Cancer Research, 2014, 20, 6504-6516.	7.0	87
14	Behavior of T7 RNA Polymerase and Mammalian RNA Polymerase II at Site-specific Cisplatin Adducts in the Template DNA. Journal of Biological Chemistry, 2003, 278, 35791-35797.	3.4	86
15	Xeroderma Pigmentosum Complementation Group A Protein (XPA) Modulates RPA-DNA Interactions via Enhanced Complex Stability and Inhibition of Strand Separation Activity. Journal of Biological Chemistry, 2002, 277, 16096-16101.	3.4	75
16	Partial Reconstitution of Human DNA Mismatch Repair In Vitro: Characterization of the Role of Human Replication Protein A. Molecular and Cellular Biology, 2002, 22, 2037-2046.	2.3	75
17	Targeted Inhibition of Replication Protein A Reveals Cytotoxic Activity, Synergy with Chemotherapeutic DNA-Damaging Agents, and Insight into Cellular Function. Cancer Research, 2010, 70, 3189-3198.	0.9	73
18	DNA Damage Induced Hyperphosphorylation of Replication Protein A. 1. Identification of Novel Sites of Phosphorylation in Response to DNA Damage. Biochemistry, 2005, 44, 8428-8437.	2.5	72

#	ARTICLE	IF	CITATIONS
19	Strand-Specific Binding of RPA and XPA to Damaged Duplex DNA. <i>Biochemistry</i> , 2002, 41, 2402-2408.	2.5	68
20	Human Replication Protein A Preferentially Binds Cisplatin-Damaged Duplex DNA in Vitro. <i>Biochemistry</i> , 1998, 37, 8808-8815.	2.5	66
21	DNA Damage Induced Hyperphosphorylation of Replication Protein A. 2. Characterization of DNA Binding Activity, Protein Interactions, and Activity in DNA Replication and Repair. <i>Biochemistry</i> , 2005, 44, 8438-8448.	2.5	62
22	Unraveling the Complexities of DNA-Dependent Protein Kinase Autophosphorylation. <i>Molecular and Cellular Biology</i> , 2014, 34, 2162-2175.	2.3	58
23	Stopped-flow Kinetic Analysis of Replication Protein A-binding DNA. <i>Journal of Biological Chemistry</i> , 2001, 276, 22630-22637.	3.4	53
24	Extracellular Tissue Transglutaminase Activates Noncanonical NF- κ B Signaling and Promotes Metastasis in Ovarian Cancer. <i>Neoplasia</i> , 2013, 15, 609-618.	5.3	52
25	Human Ku Autoantigen Binds Cisplatin-damaged DNA but Fails to Stimulate Human DNA-activated Protein Kinase. <i>Journal of Biological Chemistry</i> , 1996, 271, 13861-13867.	3.4	51
26	Complex Cisplatin-Double Strand Break (DSB) Lesions Directly Impair Cellular Non-Homologous End-Joining (NHEJ) Independent of Downstream Damage Response (DDR) Pathways. <i>Journal of Biological Chemistry</i> , 2012, 287, 24263-24272.	3.4	49
27	Pre-Steady-State Binding of Damaged DNA by XPC-hHR23B Reveals a Kinetic Mechanism for Damage Discrimination. <i>Biochemistry</i> , 2006, 45, 1961-1969.	2.5	48
28	Telomerase-associated Protein 1, HSP90, and Topoisomerase II α Associate Directly with the BLM Helicase in Immortalized Cells Using ALT and Modulate Its Helicase Activity Using Telomeric DNA Substrates. <i>Journal of Biological Chemistry</i> , 2009, 284, 14966-14977.	3.4	47
29	Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1796-1806.	4.1	47
30	DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer. <i>DNA Repair</i> , 2016, 40, 35-46.	2.8	45
31	Mechanism of DNA-Dependent Protein Kinase Inhibition by cis-Diamminedichloroplatinum(II)-Damaged DNA. <i>Biochemistry</i> , 1997, 36, 7586-7593.	2.5	42
32	Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. <i>Biochemical Pharmacology</i> , 2015, 93, 25-33.	4.4	42
33	Kinetic Analysis of the Ku-DNA Binding Activity Reveals a Redox-dependent Alteration in Protein Structure That Stimulates Dissociation of the Ku-DNA Complex. <i>Journal of Biological Chemistry</i> , 2006, 281, 13596-13603.	3.4	40
34	Differential activation of DNA-PK based on DNA strand orientation and sequence bias. <i>Nucleic Acids Research</i> , 2005, 33, 152-161.	14.5	36
35	Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 626-636.	4.1	35
36	Effects of the anticancer drug cis-diamminedichloroplatinum(II) on the activities of calf thymus DNA polymerase .epsilon.. <i>Biochemistry</i> , 1993, 32, 841-848.	2.5	34

#	ARTICLE	IF	CITATIONS
37	Cisplatin~DNA Binding Specificity of Calf High-Mobility Group 1 Protein~. <i>Biochemistry</i> , 1996, 35, 2992-3000.	2.5	34
38	Identification of Novel Small Molecule Inhibitors of the XPA Protein Using in Silico Based Screening. <i>ACS Chemical Biology</i> , 2010, 5, 953-965.	3.4	34
39	Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2013, 439, 586-590.	2.1	33
40	Nitric oxide and cisplatin resistance: NO easy answers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 4337-4338.	7.1	32
41	DNA-Dependent Conformational Changes in the Ku Heterodimer. <i>Biochemistry</i> , 2008, 47, 4359-4368.	2.5	32
42	Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 385-91.	4.1	32
43	A mechanism for DNA-PK activation requiring unique contributions from each strand of a DNA terminus and implications for microhomology-mediated nonhomologous DNA end joining. <i>Nucleic Acids Research</i> , 2008, 36, 4022-4031.	14.5	30
44	Purification and characterization of exonuclease-free Artemis: Implications for DNA-PK-dependent processing of DNA termini in NHEJ-catalyzed DSB repair. <i>DNA Repair</i> , 2010, 9, 670-677.	2.8	30
45	Coordination of DNA~PK Activation and Nuclease Processing of DNA Termini in NHEJ. <i>Antioxidants and Redox Signaling</i> , 2011, 14, 2531-2543.	5.4	29
46	Interactions of mammalian proteins with cisplatin-damaged DNA. <i>Journal of Inorganic Biochemistry</i> , 1999, 77, 83-87.	3.5	28
47	Photo-Cross-Linking of XPC~Rad23B to Cisplatin-Damaged DNA Reveals Contacts with Both Strands of the DNA Duplex and Spans the DNA Adduct. <i>Biochemistry</i> , 2010, 49, 669-678.	2.5	25
48	Synthesis of the Mammalian Telomere Lagging Strand in Vitro. <i>Journal of Biological Chemistry</i> , 1997, 272, 11678-11681.	3.4	24
49	Overexpression and Purification of Human XPA Using a Baculovirus Expression System. <i>Protein Expression and Purification</i> , 2000, 19, 1-11.	1.3	24
50	Interaction and Stimulation of Human FEN-1 Nuclease Activities by Heterogeneous Nuclear Ribonucleoprotein A1 in ~Segment Processing during Okazaki Fragment Maturation~. <i>Biochemistry</i> , 2003, 42, 15045-15052.	2.5	23
51	Targeting the OB-Folds of Replication Protein A with Small Molecules. <i>Journal of Nucleic Acids</i> , 2010, 2010, 1-11.	1.2	22
52	Discovery and development of novel DNA-PK inhibitors by targeting the unique Ku~DNA interaction. <i>Nucleic Acids Research</i> , 2020, 48, 11536-11550.	14.5	19
53	Recognition of DNA Termini by the C-Terminal Region of the Ku80 and the DNA-Dependent Protein Kinase Catalytic Subunit. <i>PLoS ONE</i> , 2015, 10, e0127321.	2.5	19
54	ATM mediates repression of DNA end-degradation in an ATP-dependent manner. <i>DNA Repair</i> , 2008, 7, 464-475.	2.8	18

#	ARTICLE	IF	CITATIONS
55	Interrogation of Nucleotide Excision Repair Capacity: Impact on Platinum-Based Cancer Therapy. Antioxidants and Redox Signaling, 2011, 14, 2465-2477.	5.4	18
56	Molecular analysis of Ku redox regulation. BMC Molecular Biology, 2009, 10, 86.	3.0	16
57	Structure-Guided Optimization of Replication Protein A (RPA)â€™DNA Interaction Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 1118-1124.	2.8	16
58	DNA substrate specificity of DNA helicase E from calf thymus. Nucleic Acids Research, 1992, 20, 6075-6080.	14.5	15
59	TRF1 Inhibits Telomere C-Strand DNA Synthesis in Vitro. Biochemistry, 2001, 40, 2426-2432.	2.5	14
60	DNA helicase E and DNA polymerase .epsilon. functionally interact for displacement synthesis. Biochemistry, 1992, 31, 9008-9015.	2.5	13
61	Exploring a structural proteinâ€™drug interactome for new therapeutics in lung cancer. Molecular BioSystems, 2014, 10, 581-591.	2.9	12
62	Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Proteinâ€™DNA Interaction. Journal of Medicinal Chemistry, 2017, 60, 8055-8070.	6.4	12
63	Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair. Frontiers in Oncology, 2022, 12, 850883.	2.8	12
64	High-mobility group 1 protein inhibits helicase catalyzed displacement of cisplatin-damaged DNA. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1354, 279-290.	2.4	11
65	Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer. Molecular Cancer Research, 2020, 18, 1699-1710.	3.4	9
66	Identification of Mre11 as a Target for Heat Radiosensitization. Radiation Research, 2011, 176, 323.	1.5	8
67	A special issue on DNA damage responses and genome maintenance. Cell Research, 2008, 18, 1-2.	12.0	6
68	OB-Folds and Genome Maintenance: Targeting Proteinâ€™DNA Interactions for Cancer Therapy. Cancers, 2021, 13, 3346.	3.7	6
69	Multiple protein-protein interactions within the DNA-PK complex are mediated by the C-terminus of Ku 80. International Journal of Biochemistry and Molecular Biology, 2012, 3, 36-45.	0.1	6
70	In Vivo Targeting Replication Protein A for Cancer Therapy. Frontiers in Oncology, 2022, 12, 826655.	2.8	6
71	Characterization of Thermally Activated Metalloenediyne Cytotoxicity in Human Melanoma Cells. Radiation Research, 2018, 190, 107-116.	1.5	5
72	Abstract 4753: Targeting nucleotide excision repair: Chemical synthetic lethality and biology-based combination therapy. , 2012, , .		4

#	ARTICLE	IF	CITATIONS
73	Intrinsic hTRF1 fluorescence quenching reveals details of telomere DNA binding activity: Impact of DNA length, structure and position of telomeric repeats. Archives of Biochemistry and Biophysics, 2010, 493, 207-212.	3.0	3
74	Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications. , 2012, , 109-117.		3
75	Targeting Nucleotide Excision Repair as a Mechanism to Increase Cisplatin Efficacy. , 2009, , 177-187.		3
76	Abstract 4623: The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.. , 2013, , .		2
77	Abstract 2829: Targeting the DNA damage response and DNA-PK signaling via small molecule Ku inhibitors. , 2018, , .		2
78	Current Advances in DNA Repair: Regulation of Enzymes and Pathways Involved in Maintaining Genomic Stability. Antioxidants and Redox Signaling, 2011, 14, 2461-2464.	5.4	1
79	Testing the Metal of ERCC2 in Predicting the Response to Platinum-Based Therapy. Cancer Discovery, 2014, 4, 1118-1119.	9.4	1
80	Small-Molecule Inhibitor Screen for DNA Repair Proteins. Methods in Molecular Biology, 2019, 1999, 217-221.	0.9	1
81	Physiological functions of protein kinase inhibitors. Exs, 2000, 89, 109-121.	1.4	1
82	DNA-Dependent Protein Kinase in Apoptosis. , 2001, 39, 693-700.		0
83	Cisplatin Sensitizes DNA To Ionizing Radiation By Impairing Non-Homologous End-Joining. , 2010, , .		0
84	Repair Of DNA Double-Strand Breaks By Non-Homologous End-Joining Is Independent Of Cisplatin-Induced Checkpoint Activation And Downstream Damage Response Pathways In A Non-Small Cell Lung Cancer Cell Culture Model. , 2011, , .		0
85	Abstract 2320: In vivo characterization of small molecule inhibitors of replication protein A: Implications for cancer therapy. , 2011, , .		0
86	Abstract LB-119: Targeting DNA-PK via small molecule inhibitors of the Ku-DNA interaction. , 2017, , .		0
87	Abstract 1416: Development of small molecule inhibitors for cancer therapy by targeting RPA and XPA nucleotide excision repair proteins. , 2017, , .		0
88	Abstract 1301: Targeting protein-DNA interactions in the DNA damage response: Lead identification and optimization for novel inhibitors of RPA and Ku. , 2019, , .		0
89	Characterization and initial demonstration of <i>in vivo</i> efficacy of a novel heat-activated metalloenediayne anti-cancer agent. International Journal of Hyperthermia, 2022, 39, 405-413.	2.5	0
90	Abstract 1406: Design and synthesis of novel cardiac glycosides by targeting the DNA damage response for cancer therapy. Cancer Research, 2022, 82, 1406-1406.	0.9	0